iBio (IBIO) Liabilities from Discontinued Operations (2022 - 2024)
iBio (IBIO) posted quarterly Liabilities from Discontinued Operations of 1933000.0 for Q1 2024, down 0.57% year-over-year from 1944000.0 in Q2 2023, and little changed quarter-over-quarter from 1936000.0 in Q4 2023.
iBio (IBIO) Liabilities from Discontinued Operations (2022 - 2024) Analysis & Trends
iBio (IBIO) has reported Liabilities from Discontinued Operations for 3 consecutive years, with 1933000.0 the latest figure, recorded in Q1 2024.
- In Q1 2024, Liabilities from Discontinued Operations fell 0.57% year-over-year to 1933000.0; the TTM figure through Mar 2024 stood at 1933000.0 (down 0.57% YoY), while the FY2023 annual figure was 1941000.0, up 3366.07% from the prior year.
- Liabilities from Discontinued Operations was little changed at 1933000.0 in Q1 2024 per IBIO's latest filing, from 1936000.0 in the prior quarter.
- Across five years, Liabilities from Discontinued Operations topped out at 1947000.0 in Q4 2022 and bottomed at 56000.0 in Q2 2022.
- Historically, Liabilities from Discontinued Operations has averaged 1670857.14 across 3 years, with a median of 1939000.0 in 2023.
- Annual changes were most pronounced in 2023 — Liabilities from Discontinued Operations surged 3366.07% — and 2024, when it fell 0.57%.
- iBio's Liabilities from Discontinued Operations stood at 1947000.0 in 2022, then decreased by 0.56% to 1936000.0 in 2023, then decreased by 0.15% to 1933000.0 in 2024.
- Business Quant data shows IBIO's Liabilities from Discontinued Operations at 1933000.0 in Q1 2024, 1936000.0 in Q4 2023, and 1939000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 1.93 Mn |
| Mar 31, 2024 | 1.93 Mn |
| Dec 31, 2023 | 1.94 Mn |
| Dec 31, 2023 | 1.94 Mn |
| Sep 30, 2023 | 1.94 Mn |
| Sep 30, 2023 | 1.94 Mn |
| Jun 30, 2023 | 1.94 Mn |
| Jun 30, 2023 | 1.94 Mn |
| Mar 31, 2023 | 1.94 Mn |
| Mar 31, 2023 | 1.94 Mn |
| Dec 31, 2022 | 1.95 Mn |
| Dec 31, 2022 | 1.95 Mn |
| Jun 30, 2022 | 56,000.00 |
| Jun 30, 2022 | 56,000.00 |